

Clear Proof Rebates Do Not Drive Up Prescription Drug Costs

Prescription drug manufacturers say that rebates and discounts negotiated by pharmacy benefit managers (PBMs) are the reason for rising drug prices. Not true. Drugmakers set prices and PBMs exist to bring prices down. Rebates were created by and continue to be offered by brand drugmakers as part of their overall pricing strategy. The evidence is clear: drug manufacturers are the one group setting high prices. The following list of prescription drugs are not rebated, but have experienced significant cost increases in 2017.

Drug Name	Indication	Manufacturer	2017 Price Increase
BANZEL	Seizures	Eisai Inc.	20.8%
EFFEXOR XR	Depression	Pfizer Inc.	19.8%
LIPITOR	High Blood Cholesterol	Pfizer Inc.	19.7%
PROGRAF	Transplant	Astellas Pharma US Inc.	18.8%
MENOPUR	Infertility	Ferring Pharmaceuticals	15.5%
FIRAZYR	Hereditary Angioedema	Shire US Inc.	9.2%
IMBRUVICA	Cancer	Janssen Pharmaceuticals Inc	8.4%
ISENTRESS	HIV	Merck & Co. Inc.	7.9%
PREZISTA	HIV	Janssen Pharmaceuticals Inc. / Johnson and Johnson	7.9%
TRIUMEQ	HIV	ViiV Healthcare	7.9%
PULMOZYME	Cystic Fibrosis	Genentech, Inc.	7.0%
STRIBILD	HIV	Gilead Sciences Inc.	6.9%
ORKAMBI	Cystic Fibrosis	Vertex Pharmaceuticals Inc.	5.0%

Studies show that PBMs will **save American consumers nearly \$2 trillion on prescription drug costs over the next decade**. Without the innovation provided by PBMs, millions of Americans would be subject to arbitrary price increases at the hands of drug manufacturers.